Role of novel drug delivery systems in overcoming the challenges associated with intraocular delivery of drugs: an overview

Sharma, DS; Gulati, M; Singh, SK; Singh, PK; Wadhwa, S

Role of novel drug delivery systems in overcoming the challenges associated with intraocular delivery of drugs: an overview

Sharma, DS Gulati, M Singh, SK Singh, PK Wadhwa, S

Permalink

Publisher:: Elsevier
Publication Type:: Chapter
Citation:: Multifunctional Nanocarriers, 2022, pp. 401-418
Issue Date:: 2022-01-01

Closed Access

	Filename	Description	Size
	20985782_11025931760005671.pdf	Published version	1.67 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Sharma, DS
dc.contributor.author	Gulati, M
dc.contributor.author	Singh, SK
dc.contributor.author	Singh, PK
dc.contributor.author	Wadhwa, S
dc.date.accessioned	2023-07-10T20:16:49Z
dc.date.available	2023-07-10T20:16:49Z
dc.date.issued	2022-01-01
dc.identifier.citation	Multifunctional Nanocarriers, 2022, pp. 401-418
dc.identifier.isbn	9780323852944
dc.identifier.uri	http://hdl.handle.net/10453/171416
dc.description.abstract	The topical route is the most common route for delivery of the drug to the eyes because of its high patient compliance and noninvasive technique. Mostly, the drug is not able to cross the barriers and is unable to reach the posterior eye segment. Success of any treatment of ocular disease depends on the targeting of the drug to the posterior segment of eye, i.e., retina by crossing or bypassing ocular barriers for the management of ocular diseases. In particular, ocular diseases have been treated by two primary modalities, i.e., topical drops and intravitreal injections. But they can cause serious complications of eyes like impaired wound healing, retinal detachment, endophthalmitis, hypertension, proteinuria, and increased risk of cardiovascular diseases. Ocular conventional systems include ophthalmic drops, eye suspensions, eye emulsions, and eye ointments are not considered most advantageous for treatment of ocular diseases as they primarily target the anterior section of eye but systemic doses boost the treatment of posterior section of eye. Mostly topically applied drug entities are removed and washed off from the eyeball by mechanism of lacrimation, tear dilution, and tear turnover ultimately causing little bioavailability of drugs. The challenges of the aforementioned existing conventional dosage forms suggest to rethink on the need for noninvasive, effective, and economical delivery systems, i.e., novel drug delivery systems. They can deliver the drug effectively to retina overcoming the challenges associated with conventional approaches.
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Multifunctional Nanocarriers
dc.relation.isbasedon	10.1016/B978-0-323-85041-4.00003-2
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Role of novel drug delivery systems in overcoming the challenges associated with intraocular delivery of drugs: an overview
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
dc.date.updated	2023-07-10T20:16:48Z
pubs.publication-status	Published

Abstract:

The topical route is the most common route for delivery of the drug to the eyes because of its high patient compliance and noninvasive technique. Mostly, the drug is not able to cross the barriers and is unable to reach the posterior eye segment. Success of any treatment of ocular disease depends on the targeting of the drug to the posterior segment of eye, i.e., retina by crossing or bypassing ocular barriers for the management of ocular diseases. In particular, ocular diseases have been treated by two primary modalities, i.e., topical drops and intravitreal injections. But they can cause serious complications of eyes like impaired wound healing, retinal detachment, endophthalmitis, hypertension, proteinuria, and increased risk of cardiovascular diseases. Ocular conventional systems include ophthalmic drops, eye suspensions, eye emulsions, and eye ointments are not considered most advantageous for treatment of ocular diseases as they primarily target the anterior section of eye but systemic doses boost the treatment of posterior section of eye. Mostly topically applied drug entities are removed and washed off from the eyeball by mechanism of lacrimation, tear dilution, and tear turnover ultimately causing little bioavailability of drugs. The challenges of the aforementioned existing conventional dosage forms suggest to rethink on the need for noninvasive, effective, and economical delivery systems, i.e., novel drug delivery systems. They can deliver the drug effectively to retina overcoming the challenges associated with conventional approaches.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/171416